Chipscreen’s New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ — On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as “Chipscreen” and with stock code 688321.SH) received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration…